Neutra Life Sciences Expands Clinical Research Capabilities Through New Joint Ventures

Neutra Life Sciences, a subsidiary of Neutra Corp (OTC: NTRR), is making significant strides in the clinical research industry by announcing new joint venture partnerships. These partnerships, spanning podiatry, radiation oncology, and dermatology, mark a strategic expansion for the company, enabling it to cater to a wider patient population and address the increasing demand for specialized clinical research services.

The new joint venture sites include Epic Foot & Ankle Centers (www.epicfootandankle.com), Aspire Hospital Cancer Centers (www.aspirehealthcorp.com), and Radiant Dermatology & Aesthetics Clinic (www.radiantdermtx.com). This expansion into multiple medical specialties positions Neutra Life Sciences as a versatile player in the clinical research field, capable of supporting a broader spectrum of therapeutic areas.

Sydney Jim, President and CEO of Neutra Corp, emphasized the importance of this growth, stating, 'Our growth reflects the increasing demand for high-quality, integrated clinical research solutions.' By collaborating with established private practices, Neutra Life Sciences aims to enhance its service offerings and contribute to innovation in patient care and research.

Looking forward, Neutra Life Sciences plans to continue its expansion into additional specialties, further solidifying its role in accelerating the development of innovative treatments. This strategic focus aligns with the company's decision to wind down its hemp-based cannabis subsidiary, VIVIS Corporation, to concentrate on the life sciences sector. This shift underscores Neutra's commitment to areas with greater regulatory stability and long-term market potential, such as clinical research and biotechnology.

Neutra Life Sciences' expansion is a testament to the growing importance of diverse and specialized clinical research services in advancing healthcare. By broadening its network of clinical research sites, the company is not only meeting the current demands of the industry but also paving the way for future innovations in patient care and treatment development.